| ￥2300 | |
| Z05825-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 73.1 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 90-115 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Siglec-5/CD170 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
Siglec-5/CD170 hFc Chimera, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%. »
| Target Background | Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding to PSGL1. |
| Synonyms | CD170; CD33 antigen-like 2; CD33L2; OBBP2; Siglec5; SIGLEC5; OB-BP2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
